The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 821
Ginsberg, H. N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00031-5
Thembane, N., & Madlala, M. (2023) · Student s Journal of Health Research Africa · doi:10.51168/sjhrafrica.v4i6.351
Xu, C., Chen, S., Du, F., Zong, A., Xu, T., & You, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2311338/v2
Chen, X. F., Fan, E., Zhang, X., Jieensihan, A., Wang, S., Guo, N., Zhao, H., Abuduaini, Y., & Wang, H. (2023) · doi:10.22541/au.168963387.75502925/v1
Rodrigues, S., Dias, V. E., Volpe, C. M. O., Barbuto, C., Padilha, H. T., & Nogueira‐Machado, J. A. (2023) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2023/v35i195166
Zhong-ping, W., Geng, Y., Hua, M., Ge, R., & Bai, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3255172/v1
Guo, S., Han, Z., Cheng, W., Zhang, Z., Liu, J., Wang, Y., Wang, X., Yan, H., & Wang, R. (2023) · Research Square · doi:10.21203/rs.3.rs-3351366/v1
Pan, Y., Qian, S., & Xu, G. (2023) · Research Square · doi:10.21203/rs.3.rs-3498743/v1
Zachariah, G. A. (2023) · Indian Heart Journal · doi:10.1016/j.ihj.2023.11.004 · Cited by 5
Haque, M. N., & Maria, S. T. (2024) · Bangladesh Heart Journal · doi:10.3329/bhj.v39i1.70672
Mohammadi, M., Namayandeh, S. M., Mirzaei, M., Shahi, M. A., & Bafighi, S. M. S. (2024) · Research Square · doi:10.21203/rs.3.rs-3829808/v1 · Cited by 1
Savoir interpréter le HDL cholestérol
Gallo, A., & Chalopin, S. (2024) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2024.01.013
fang, L., Zhao, S., & Liang, P. (2024) · Research Square · doi:10.21203/rs.3.rs-3921273/v1
The high-density lipoprotein: Attribute matters rather than amount in therapeutic arena
AlJadir, S. J. (2023) · Endocrinology&Metabolism International Journal · doi:10.15406/emij.2023.11.00334
Li, Z., Zhang, W., He, L., Cui, H., Wang, Y., Wu, X., Zhao, X., Yan, P., Yang, C., Xiao, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24136385
Wei, R., & Huang, M. (2024) · Research Square · doi:10.21203/rs.3.rs-4209750/v1
Quiroga, A. G., Bustamante-Cabrejo, A., Caballero-Alvarado, J., Zavaleta-Corvera, C., & Burgos-Chávez, O. A. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5740
Berkowitz, L., Flaherty, S., Kitayama, S., Karasawa, M., Kawakami, N., Rigotti, A., & Coe, C. L. (2024) · Antioxidants · doi:10.3390/antiox13121434 · Cited by 1
Wang, G. (2024) · Springer eBooks · doi:10.1007/978-981-97-6512-6_2
Extremely Elevated High Density Lipoprotein Post Statin Usage: A Case Report
Ghosh, A., & Neepa, C. (2023) · Journal of Applied Biochemistry & Laboratory Medicine · doi:10.5005/jablm-11031-04103
Teles, B. S. B. D. S., Ramalho, S. H. R., Bittencourt, M. S., Benseñor, I. M., Blaha, M. J., Toth, P. P., Jones, S. R., Santos, R. D., Lotufo, P. A., & de Carvalho, L. S. F. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf215
Ahmadizar, F., Natarajan, P., & Paruchuri, K. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf265
Taradeh, M., Hardy, L. M., Dahik, V. D., Lhomme, M., Wang, H., Reydellet, C., Materne, C., Pukar, K. C., Bun, E., Clemessy, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.27.656492
Self-citationNanoparticle-enabled plasma proteomics of a mouse atherosclerosis modelPreprint
Delwarde, C., Matamalas, J. T., Chelvanambi, S., Kasai, T., Shlayen, G., Pestana, D. V. S., Zamani, M., Aikawa, E. R., Aikawa, M., & Singh, S. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.01.667173
Pharmacological targets in metabolic syndrome related dyslipidemia
Cariño‐Cortés, R., Manuel, M.-P. V., Ortiz, M. I., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00005-6
Pei, J., Zaid, M., Wu, Y., Wang, N., Liu, X., Zhao, Q., Jiang, Y., Xu, W., & Zhao, G. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-091516
Fan, L., Jiang, H., & Zhang, Z. (2025) · BioData Mining · doi:10.1186/s13040-025-00484-3 · Cited by 1
Cui, B., Zhang, X., Guo, G., Liu, W., & Sun, C. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2567229
High-Density Lipoprotein-Specific Phospholipid Efflux Assay
Neufeld, E. B., Sato, M., & Remaley, A. T. (2025) · Journal of Visualized Experiments · doi:10.3791/68947
Luo, M.-Y., Zhang, F.-L., Lv, S., Song, Y., Yu, Y., Guo, Z., & Yang, Y. (2025) · Acta Neurologica Scandinavica · doi:10.1155/ane/1668467
Evaluation of lipid parameters and correlations in patients with clinical atherosclerosis
Kuraş, S. (2025) · Developments and Experiments in Health and Medicine · doi:10.18614/dehm.1813843
The association between serum uric acid and homocysteine is mediated by metabolic risk factors
Zhao, L., Zhou, H., Xiao, Z., & Qiu, X. (2025) · Scientific Reports · doi:10.1038/s41598-025-22270-1
Loschinski, R., Karl, F., Drettwan, D., Wittmann, J., Jacobs, B., Völkl, S., Bruns, H., Mackensen, A., & Mougiakakos, D. (2025) · Clinical & Translational Immunology · doi:10.1002/cti2.70060
Sheng, C., Zhou, R., Wang, H., Jin, L., Lin, G., Yang, P., & Wang, W. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042610
Yoo, J., Rhee, C. K., Jo, Y. S., & Choi, J. Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-31387-2
Guirgis, F. W., Leeuwenburgh, C., Moldawer, L. L., Ghita, G. L., Black, L. P., Henson, M., DeVos, E., Holden, D. C., Efron, P. A., Reddy, S. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14633694
Chen, Z., Ding, S., Wang, Y. P., Chen, L., Mao, J. Y., Yang, Y., Sun, J. T., & Yang, K. (2020) · Figshare · doi:10.6084/m9.figshare.13331787
Montazeri Namin, S., Moradi, A., Tavolinejad, H., Vasheghani-Farahani, A., Jalali, A., Pashang, M., Sadeghian, S., Bagheri, J., Mansourian, S., Mehrani, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26702590
Chen, Z., Ding, S., Wang, Y. P., Chen, L., Mao, J. Y., Yang, Y., Sun, J. T., & Yang, K. (2020) · Figshare · doi:10.6084/m9.figshare.13331796
Tan, L., Ouyang, Z., Chen, Z., Sun, F., Guo, H., Wang, F., Mulder, M. T., Sun, Y., Lu, X., Zhang, J. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608970
谭仑波, Ouyang, Z., Chen, Z., Sun, F., Guo, H., Wang, F., Mulder, M. T., Sun, Y., Lu, X., Zhang, J. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608973
Chen, Z., Ding, S., Wang, Y. P., Chen, L., Mao, J. Y., Yang, Y., Sun, J. T., & Yang, K. (2020) · Figshare · doi:10.6084/m9.figshare.13331790
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20155656
Gordon, S., Amar, M. J., Jeiran, K., Stagliano, M., Staller, E., Playford, M. P., Mehta, N. N., Vaisar, T., & Remaley, A. T. (2020) · Figshare · doi:10.6084/m9.figshare.12845703
Zhang, L., Zhang, W., He, L., Cui, H., Wang, Y., Wu, X., Zhao, X., Yan, P., Yang, C., Xiao, C., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24136391
Chen, Z., Ding, S., Wang, Y. P., Chen, L., Mao, J. Y., Yang, Y., Sun, J. T., & Yang, K. (2020) · Figshare · doi:10.6084/m9.figshare.13331793
Jin, J., Zhao, X., Zhu, C., Li, M., Wang, J., Fan, Y., Liu, C., Shen, C., & Yang, R. (2023) · Figshare · doi:10.6084/m9.figshare.23803103
Tan, L., Ouyang, Z., Chen, Z., Sun, F., Guo, H., Wang, F., Mulder, M. T., Sun, Y., Lu, X., Zhang, J. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22608976
Guirgis, F. W., Leeuwenburgh, C., Moldawer, L. L., Ghita, G. L., Black, L. P., Henson, M., DeVos, E., Holden, D. C., Efron, P., Reddy, S. T., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14633697
Cao, J., Li, R., He, T., Zhang, L., Liu, H., & Wu, X. (2024) · Figshare · doi:10.6084/m9.figshare.26587554
Chen, Y.-F., & Wang, L.-H. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2607806
Li, Y., Liu, Y., & Cheng, Y. (2026) · Biochemistry Research International · doi:10.1155/bri/8149388
Age- and sex-dependent gene expression landscapes in dyslipidaemia-driven atherosclerosis
Guzzi, P. H., Pedace, E., & Veltri, P. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00771-x
Oe, M., Fujihara, K., Ikeda, K., Shimayama, C., Sato, T., OSAWA, T., Matsubayashi, Y., Kodama, S., Yamada, T., & Sone, H. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70156
Cheang, N., Chen, X., Zhang, H., Su, Q., & Du, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s581946
Lipid-Mediated Mechanisms in Atherosclerosis
Caudle, W., Sarhan, M., Liu, Q., Martinez, J., Hodge, J., & Fan, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00059-5
Clinical Assessment of Anti-Atherogenic Function of HighDensity Lipoprotein (HDL)
Ma, F. (2018) · theses.fr (ABES) · doi:10.70675/aec01babza8edz47a2zb4d4zc7c3be00b185
Hardy, L. M. (2019) · theses.fr (ABES) · doi:10.70675/2f5f4b0dzc92fz4cb4z9c5bzeb6d3fd3e791
Hu, X., Yang, X., Zhu, Z., Yang, Z., Wang, P., Wu, M., & Zhang, N. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1768784
A functional SNP rs12718466 in APOA1 promoter modulates gene expression via interaction with SOX7
Aita, Y., Takeuchi, Y., Masuda, Y., Saber, Z. M., Karkoutly, S., Tao, D., Ye, C., Mendsaikhan, T., Saikawa, R., Kondo, Y., et al. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113101
The Clinical Utility of MPO / PON1 and MPO / HDL ‐C Ratios in Cardiovascular Risk Assessment
Meng, W., & Zhu, S. (2026) · Therapeutic Apheresis and Dialysis · doi:10.1002/1744-9987.70152
Assessment of Cardiovascular Disease Risk Across the Lifespan
Tapp, D. N., Haygood, D., Tipler, P., Tzoumas, A., & Quesada, O. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_2
Koutsogianni, A. D., Tatsis, G., Telli, C., Stamoulis, K., Milionis, H. J., Liberopoulos, E. N., Tselepis, A. D., & Tellis, C. C. (2026) · Applied Biosciences · doi:10.3390/applbiosci5020040
Repositioning of niacin in atherosclerotic cardiovascular disease
Li, W., Bai, Z., Li, C., Lu, S., Wang, Y., Huang, D., Zhang, H., Yuan, J., Zhen, X., & Liu, Y. (2026) · PharmaNutrition · doi:10.1016/j.phanu.2026.100506
Zhou, J.-Q., Zhang, H., Guo, L.-Z., Wang, J., Chen, Y., Jiang, E.-D., Peng, J., Gao, H., Sun, Y.-H., Zhu, M.-Y., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01831-8
Deniz, İ., Cabbar, A. T., Akdeniz, F. T., İşbir, T., & Yılmaz, S. G. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114206
Guo, R., Xian-zhe, Z., Yang, Y.-L., Chen, J.-X., Gao, J.-F., & Ke, X. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08189-6
Li, C., Xu, M., Lu, S., Yan, Y., Suo, X., Han, J., Ye, H., Bo, Y., & Lyu, Q. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109007
Xu, J.-J., Ma, J., Shang, W., Hu, D., & Dang, Y.-Q. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.117368
Li, Y., Ni, J., Li, Y., Zhao, S., & Chen, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1750848
Ji, D., Xie, L., Wang, X. X., Gao, Z., Jiang, X., Lu, H., Ye, X., Zhang, T., Zhang, Z., Cao, Y. J., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9824642/v1
Zhang, Z., Lei, X., Lin, X., Xie, C., Cai, D., Weng, S., Zhao, L., Chen, M., Hou, X., & Su, K. (2026) · Science Progress · doi:10.1177/00368504261459771
Wu, W., (417962), P. F., Cai, Z., Wang, Y., Wu, K., Zheng, H., Chen, G., Chen, Z., Lan, Y., Chen, Y., et al. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00302-7
Korovina, O. O., Metelskaya, V. A., Валерьевна, Д. Н., Timofeev, J. S., Chernyshenko, E. G., & Drapkina, O. M. (2026) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2026-4790
Ma, Z.-S., Mo, Z.-W., Cao, H.-Y., Liu, Y.-F., Kang, Y.-T., Chen, J.-Y., Lyu, C.-Y., Chen, L., Ou, Z., Li, Y., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101090
Yang, Y., Zhang, M., Xie, C., Huang, Y. N., Cheng, H., Li, Y., Cai, J., & Zhang, Z. (2026) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2026.120435
Liu, Y., Yu, Y., 范馨月, Cai, Y., & Tian, W. (2026) · Biomedicines · doi:10.3390/biomedicines14071503
Kim, S. H., Kim, S., Lee, N. K., & Lee, S. W. (2026) · Healthcare · doi:10.3390/healthcare14131959
Li, Z., Liu, W., Yi, K., & You, T. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.06.010
Genetic and molecular signatures highlight diverse pathways linking obesity to type 2 diabetes
Mutie, P. M., Stojanovic, T., Faro, V. L., Karlsson, T., & Johansson, Å. (2026) · Nature Communications · doi:10.1038/s41467-026-74675-9 · Cited by 1
Jia, C., Wu, W., Liu, Y., & Chen, J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.004
Cai, Y. N., Li, K., Ma, H., Wu, J., & Zheng, Y. (2026) · Antioxidants · doi:10.3390/antiox15070864
Mora‐Godínez, S., Marín‐Obispo, L. M., Mellado-Negrete, A., de la Garza, A. L., Tamez‐Rivera, O., Navarro-Guerra, M., Telles-Ramirez, B., Martínez-Ledesma, E., Castaño‐Moreno, E., Senés‐Guerrero, C., et al. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0194
Ptaszek, B., Podsiadło, S., Niżankowski, R., Mika, P., & Sadowska‐Krępa, E. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1858294
Rajab, E., Moin, A. S. M., Nandakumar, M., Sathyapalan, T., Butler, A. E., & Atkin, S. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156656
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_13
Černiauskas, L., Aleknavičiūtė-Valienė, G., Arbaciauskaite, S., Mytzka, N., Allelein, S., Bikulčienė, I., & Karčiauskaitė, D. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1831078
Li, D., Dong, J., Zhang, Z., Yang, X., & Zhang, J. (2026) · Science Progress · doi:10.1177/00368504261473732
Ünğan, İ., & Asoğlu, R. (2026) · Diagnostics · doi:10.3390/diagnostics16152412
Chvatal‐Medina, M., Kunutsor, S. K., Li, Y., van Vilsteren, F. G. I., Post, A., Connelly, M. A., Moshage, H. J., Bakker, S. J. L., de Meijer, V. E., & Dullaart, R. P. F. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.029
Ruan, G., Guo, X., Zhang, W., & Cai, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1895584
HDL-associated proteins affecting CVD and systemic inflammation
Delk, S. C., & Reddy, S. T. (2026) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001052
Riskawati, Y. K., Nur, A., Mustika, D., Hartono, B., Iwanto, G. M., Saraswati, S. P. C. V., & Indradmojo, C. (2026) · Journal of Pharmaceutical And Sciences · doi:10.36490/journal-jps.com.v9i3.1804
Ishibashi, R., Koshizaka, M., Hirayama, K., Sakai, T., Tatsumi, T., Takatsuna, Y., Baba, T., Maezawa, Y., & Yokote, K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71223
Nanoparticle-Enabled Plasma Proteomics of Experimental Atherosclerosis in Mice
Delwarde, C., Matamalas, J. T., Chelvanambi, S., Kasai, T., Shlayen, G., Pestana, D. V. S., Zamani, M., Aikawa, E. R., Aikawa, M., & Singh, S. A. (2026) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2026.101649
Feng, R., Wang, Y., Li, D., & Chen, J. (2026) · Burns · doi:10.1016/j.burns.2026.108188
Site-Specific Apo AI Glycation Impairs HDL Function and Promotes Atherosclerosis in Diabetes
Dai, Y., Li, Q., Ding, F., Chen, S., Li, F., Gu, R., Wang, Q., Li, L., Zhang, J., Wang, X. Q., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.078171
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
